BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted four newly-hired employees stock options to purchase an aggregate of 57,100 shares, and restricted stock units (RSUs) covering an aggregate of 46,400 shares, of BioCryst common stock. The options and RSUs were granted as of December 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).